Preliminary Observation Of Clinical Efficacy Of Cerebrolysin Treatment Of Traumatic Brain Injury(TBI)

ObjectivesThe goal of the experiment is to discuss the clinical effect of the Cerebrolysin as theadditional treatment of the standard treatment program during the treatment period, therehabilitation period and the forward period for the traumatic brain injury patients(GCS7-12).Subjects and methods60patients with traumatic brain injury (TBI) and GCS(7-12) were admitted to theneurosurgery department of Taishan Medical College Affiliated Hospital from February2010to September2012.60cases of TBI patients were divided into experimental group(35cases) and control group (25cases) in accordance with the principle of randomallocation.60patients were treated in accordance with the standard regimen of brain injurytreatment guidelines, while the experimental group based on the standard treatmentprogram were appended the same dose of Cerebrolysin medication in addition(Table1).The mini-mental state check (MMSE), the processing speed index (PSI)(WALS-thirdedition) and the long-term quality of life evaluation were used to evaluate the efficacy ofthe Cerebrolysin drug for patients with traumatic brain injury (TBI)of the two groupsduring30days,90days and180days respectively after hospital treatment. Regard the sidereaction scale (DOTES TWIS), recorded adverse events, and the mortality of three monthsas the security indicators to assess the security of the drug in this trial. Use SPSS13.0statistical software for statistical analysis. Measurement data withx s, t-test between thetwo groups, the difference was statistically significant (p <0.05).Results①60cases of patients met with the inclusion standard,7cases quit for some reason,so a total of53samples were included in the study results. ②Comparisons between the experimental group and control group during the first30days,90days and180days after treatment, the MMSE, PSI, and the long-term quality oflife three indicators were tested between the experimental group and the control group: thedifferences had statistical significance(P<0.05). Especially in the long-term quality of lifeaspect,180days, the experimental group average score (4.74±0.51), the control groupaverage score (4.09±0.43), the two groups had obvious differences.③after3months,7cases of death, cause of death were all lung infections.4cases inthe experimental group, accounting for11.4%;3cases in the control group, accounting for12%, the mortality rate between the two groups had no significant differences.ConclusionsThe Cerebrolysin for traumatic brain injury patients (GCS7-12) as an additionaltreatment could obviously improve the scores of three indicators (MMSE, PSI, andlong-term quality of life) during the first30days,90days and180days after treatment,especially in the long-term quality of life aspect, the Cerebrolysin is an effective and safedrug after preliminary verification which provides the basis for clinical treatment forpatients recovery with traumatic craniocerebral injury.